Airway Remodeling in Asthma  by Sumi, Yuki & Hamid, Qutayba
Allergology International Vol 56, No4, 2007 www.jsaweb.jp 341
Airway Remodeling in Asthma
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ABSTRACT
Airway remodeling can be defined as changes in the composition, content, and organization of the cellular and
molecular constituents of the airway wall. Airway remodeling is a characteristic feature of asthma, and has im-
portant functional implications. These structural changes include epithelial detachment, subepithelial fibrosis,
increased airway smooth muscle (ASM) mass, decreased distance between epithelium and ASM cells, goblet
cell hyperplasia, mucus gland hyperplasia, proliferation of blood vessels and airway edema and changes in the
cartilage. Each can contribute to airway hyperreactivity (AHR), and may eventually lead to irreversible airflow
obstruction with disease progression.
Structural changes can be observed from early onset of the disease and thus remodeling is thought to be char-
acteristic of asthma. Some aspects of airway remodeling can be explained as a consequence of TH2 inflamma-
tion, although it has also been suggested that the exaggerated inflammation and remodeling seen in asthmatic
airways is the consequence of abnormal injury and repair responses stemming from the susceptibility of bron-
chial epithelia to components of the inhaled environment. According to this view, remodeling occurs by way of a
noninflammatory mechanism, where inflammation of airways and altered structure and function of the airways
are parallel and interacting factors.
Airway remodeling in established asthma is poorly responsive to current therapies, such as inhalation of corti-
costeroids and administration of β2-agonists, antileukotrienes, and theophylline.
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INTRODUCTION
Asthma is characterized by inflammation of the air-
way wall, variable airway limitation andor airway hy-
perreactivity (AHR) . Characteristic structural
changes in the airways of asthma patients, described
as airway remodeling, are related to the severity of
the disease. These structural changes include epithe-
lial detachment, subepithelial fibrosis, increased air-
way smooth muscle (ASM) mass, decreased distance
between ASM and epithelium, mucous gland and
goblet cell hyperplasia, proliferation of blood vessels,
and development of airway edema.
Historically, asthma is defined as a chronic inflam-
matory disorder of airways in which many cells play a
role. Some aspects of airway remodeling can be ex-
plained as a consequence of TH2 inflammation, and
until recently, airway remodeling has only been
thought of as a secondary phenomenon, representing
a repair response to inflammation and developing late
in the disease process as a consequence of persistent
inflammation.
Recent studies, however, have shown that airway
remodeling is observed from early onset of the dis-
ease and may, therefore, be characteristic of asthma.
Morphometry has revealed that airway remodeling of
asthmatic airways accounts for a large component of
AHR and excessive airway narrowing. Since remodel-
ing processes occur in parallel to, or may even be
obligatory for, the establishment of persistent inflam-
mation, the pathogenesis of airway remodeling and
the implications of therapeutic interventions that are
designed to diminish airway remodeling remain im-
portant areas of research. Although there is some evi-
dence that points to the development of promising
therapeutic strategies, particularly in relation to cyste-
inyl leukotrienes, the efficacy of existing anti-asthma
therapies for the treatment of airway remodelling
continues to be debated.
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Fig. 1 Epithelial detachment is a characteristic feature of 
airway remodeling.
Fig. 2 Subepithelial fibrosis from patient with mild asthma 
(Van Gieson stainin)
Fig. 3 Subepithelial fibrosis from patient with severe 
asthma (Van Gieson stainin)
AIRWAY REMODELING
EPITHELIAL DETACHMENT
Epithelial detachment is a characteristic feature of
airway remodeling (Fig. 1),1 although it is not uncom-
mon to find epithelial detachment in bronchial biopsy
specimens from healthy subjects.2 However, epithe-
lial detachment has also been observed in postmor-
tem studies and increase in epithelial cell has been
reported in bronchoalveolar lavage (BAL) and spu-
tum analysis, suggesting that it is not merely an arti-
fact.3,4 Using TUNEL and p85 PARP staining, it has
been shown that bronchial epithelial cells in patients
with asthma undergo more apoptosis than do epithe-
lial cells in normal controls.5,6 Epithelial damage may,
in part, be a consequence of ongoing inflammation6,7
or mechanical stress caused by bronchoconstriction,8
but also may reflect host susceptibility factors.5,9 Re-
cent studies suggest a change in the phenotype of
epithelial cells in asthmatic subjects and an increase
in the ability of these cells to produce cytokines,
chemokines, and profibrotic growth factors.10
SUBEPITHELIAL FIBROSIS
Subepithelial fibrosis is an important feature of airway
remodeling that can range from simple thickening
(Fig. 2) to extensive fibrosis (Fig. 3). In asthmatics,
the true basement membrane is of normal appear-
ance on electron microscopic examination.11 Beneath
this layer, in control subjects, there is a loose array of
collagen fibrils. In contrast, in asthmatic subjects, this
layer is replaced by a dense network of collagen fi-
brils.11 Fibrosis of this sort is due to increased deposi-
tion of extracellular matrix, particularly collagen type
I and III, fibronectin, and proteoglycans. This in-
creased deposition of extracellular matrix is due to fi-
broblast activation,11 a result of upregulation of a
number of cytokines and growth factors, such as tu-
mor growth factor beta (TGF-β) and interleukin 11
(IL-11), which are produced by both structural cells
and inflamed cells, particularly eosinophils.
INCREASE IN AIRWAY SMOOTH MUSCLE MASS
An increase in airway smooth muscle (ASM) mass is
a common observation in asthmatic airways,12 and
can be demonstrated in endoscopic biopsy specimens
(Fig. 4). There is little doubt that an increase in ASM
mass in the airways of asthmatic patients is com-
prised, in part, by hyperplasia.13-16 Increases in ASM
cell number might occur through increased rates of
division,17 decreased rates of apoptosis18 or, more
speculatively, through migration of mesenchymal
cells to ASM bundles.19-24
One reason why ASM cells in asthma patients pro-
liferate faster than cells from nonasthmatic patients
may be a result of stimulation of ASM by mitogenic
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Fig. 4 Increases in smooth muscle mass could be demon
strated in endoscopic biopsy specimens, particularly in 
those from patients with severe asthma. Smooth muscle 
cels could be demonstrated in close proximity to epithelial 
cels
Fig. 5 Hematoxylin and eosin preparation from a biopsy 
specimen of an asthmatic subject shows smooth muscle 
bundles close to the epithelium.
Fig. 6 Model representing the migration of ASMCs toward 
the epithelium, possibly mediated by chemokines.
Stimuli
Chemotactic
gradient
Migration of ASMC
or inflammatory stimuli. To date, mitogenic stimuli
that have been identified include TGF-β, EGF, IGF,
PDGF isoforms, FGF-2, β-hexosaminidases, β-
glucuronidase, α-thrombin, tryptase, sphingosine 1-
phosphate, endothelin-1, substance P, phenylephrine,
serotonin, thromboxane A2, leukotriene D4, me-
chanical stress and reactive oxygen species (ROS).25
The other explanation may be that the profile of ex-
tracellular matrix protein components is altered in
asthmatic cells and this altered profile may have the
potential to influence the proliferation of these cells.26
Moreover, one recent study has shown that ASM
cells cultured from biopsies from patients with
asthma lack the transcription factor CEBPα that in-
hibits proliferation, whereas this is not seen in control
cases.27
Hypertrophy is defined as the increased size of
constituent cells and there are conflicting reports as
to the significance of increased ASM mass stemming
from hypertrophy. Autopsy and airway biopsy studies
have led to varying conclusions regarding the mani-
festation of hypertrophy in larger airways. It has been
shown that cell diameters are increased in some of
asthmatics across the whole airway28 and in proximal
airways of patients with severe persistent asthma.29
In these studies, hypertrophy is defined as increased
width of smooth muscle cells, and results may be
subject to artifacts associated with shortening. On the
other hand one group, using a stereologic approach,
did not find evidence of ASM hypertrophy in bron-
chial biopsies of patients with mild to moderate
asthma.30 It has been suggested that increased levels
of stretch, TGF-β, IL-1β and cardiotrophin may be hy-
pertrophic influences on human ASM.31
Airway smooth muscle cells in asthmatic patients
can be seen in close proximity to epithelial cells (Fig.
5). This may result from conversion of mesenchymal
cells to ASM cells or migration of ASM cells toward
the epithelium (Fig. 6).32 Whether or not this phe-
nomenon occurs in vivo remains unknown.
CHANGE OF AIRWAY SMOOTH MUSCLE CELLS
There is strong evidence to suggest that smooth mus-
cle cells in asthma can act as inflammatory cells
through their increased capacity to produce chemoki-
nes and cytokines33 (Fig. 7). Airway remodeling may
be a result of the action of some of these secreted in-
flammatory mediators.
Emerging evidence also suggests ASM contraction
per se is changed in asthmatic airways by the inflam-
matory milieu.34
MUCUS GLAND AND GOBLET CELL HYPER-
PLASIA
An additional feature of airway remodeling is in-
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Fig. 7 ASMCs express a wide variety of mediators in-
volved in asthma pathogenesis, including cytokines, che-
mokines, growth factors, and lipid mediators. LIF, leukocyte 
inhibitory factor; TARC, thymus- and activation-regulated 
chemokine; PDGF, platelet-derived growth factor; PGE2, 
prostaglandin E2; SCF, stem cel factor; VEGF, vascular en-
dothelial growth factor; ADAM, a disintegrin and metalopro-
tease; PLA2, phospholipase A2.
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Fig. 8 An example of mucus gland hyperplasia in biopsy 
specimens from asthmatic subjects.
creased numbers of goblet cells in the airway epithe-
lia and increased size of submucosal glands (Fig. 8)
leading to excessive mucus production. Mucus hy-
persecretion may eventually lead to airflow obstruc-
tion. IL-9 and IL-13 can induce mucus hypersecre-
tion.35-38
VASCULAR CHANGE AND AIRWAY EDEMA
Changes in the airway wall microvasculature that
come about as a consequence of angiogenesis can
contribute to airway wall edema. Increased airway
vascularity has been demonstrated in bronchoscopic
biopsies of patients with mild asthma39 and in the
bronchial mucosa of both stable and newly diagnosed
asthma patients using a novel bronchovideoscope
technique.40 This increased vascularity is closely as-
sociated with increased expression of the multifunc-
tional angiogenic and permeability factor vascular en-
dothelial growth factor (VEGF),41 which is well
known for its capacity to induce edema.
CARTILAGINOUS CHANGE
Airway cartilage is an important determinant of wall
stiffness and integrity. Structural and biochemical
changes in cartilage, therefore, will have an effect on
airway function. Both decreased volume of the carti-
lage and fibronectin deposition have been observed
in asthmatic airways.42 These alterations in cartilage
integrity may result in more powerful bronchocon-
striction from ASM load reduction.
PATHOPHYSIOLOGY
AIRWAY NARROWING
Airway narrowing is the final common pathway lead-
ing to symptoms and physiological changes in
asthma. Airway edema, mucus hypersecretion, and
airway thickening due to airway remodeling and air-
way smooth muscle contraction all contribute to the
development of airway narrowing in asthma. Re-
cently, peripheral airways, including lung tissue, have
been recognized as a predominant site of airflow ob-
struction in asthmatics. Yanai et al.,43 for example,
have demonstrated dramatically increased contribu-
tions of distal airways to the total lung resistance in
patients who have moderate to severe asthma, as
compared to nonasthmatics or to patients who have
mild asthma.
AIRWAY HYPERREACTIVITY
Airway hyperreactivity is a characteristic functional
abnormality of asthma which is linked to both inflam-
mation and airway dysfunction. It is partially revers-
ible with therapy. It has been suggested that in-
creased volume and contractility of airway smooth
muscle cells causes excessive contraction.44 In addi-
tion, edematous thickening of airway walls, along
with structural changes in the wall itself, amplify air-
way narrowing for purely geometric reasons. Thick-
ening of the adventitial layer between the ASM and
the surrounding parenchyma of this layer might also
increase the ability of the ASM to narrow the airway.
Lung parenchymal recoil provides an important load
for ASM, and thickening of this layer functionally un-
couples the ASM from the surrounding recoil. The
muscle is thus able to shorten to a greater degree be-
fore the surrounding parenchyma is distorted than it
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would if the layer were not thickened.45
Some patients with severe asthma develop progres-
sive, persistent airflow limitation. They show longer
disease duration, a greater inflammatory process and
more airway abnormalities, further suggesting that
airway remodeling may account for the reduced lung
function associated with asthma.46
Although remodeling is believed to enhance airway
narrowing, it might also protect against excessive
narrowing. Lambert et al.47 have suggested that when
airways narrow, the folding of the mucosal mem-
brane internal to the ASM layer provides a load to the
muscle. Thickening and stiffening of this layer might
increase the load and attenuate the ability of ASM to
narrow the airway lumen. Although thickening of the
inner wall will undoubtedly enhance the effect of
ASM shortening, this thickening itself might attenu-
ate the ability of the muscle to shorten.
PATHOGENESIS OF AIRWAY REMODELING
Asthma is a TH2-mediated inflammatory response
and TH2 cells orchestrate many features of airway re-
modeling in asthma.48
Eosinophilic inflammation in the airway is the re-
sult of TH-2 inflammation. Eosinophils are developed
in the bone marrow under the influence of IL-4, IL-13,
and GM-CSF. TH-2-mediated cytokines also control
their movement to the lung and their activation.49
Eosinophils are the main source of TGF-β which is
the most potent profibrotic cytokine.
TH-2 cytokines also promote the production leu-
kotrienes related to airway remodeling. IL-4 and IL-13
stimulation followed by CD40 L stimulation by acti-
vated T cells drives B cells to undergo an immuno-
globulin isotype switch, shifting from IgM to IgE.50
Mast cells constitutively express FcRI (a high affin-
ity receptor for IgE) and, through the binding of IgE,
mast cells are activated, leading to degranulation, the
production of lipid mediators, and the generation of
various cytokines and chemokines.
TH2 cytokines, including IL-4, IL-5, IL-9 and IL-13,
can lead to goblet cell metaplasia.51 IL-9 appears to
play a major role and has been shown to induce mu-
cus gene expression in airway epithelial cells.52
Some evidence, however, shows that TH2 airway
inflammation is not the only cause of airway remodel-
ing. First, structural changes in established asthma
are poorly responsive to corticosteroids.53 Second,
changes induced by remodeling have been observed
in childhood asthma and precede the development of
the disease,54-56 indicating that the process begins
early in the development of asthma and might occur
in parallel with inflammation or even be required for
the establishment of persistent inflammation. More-
over, inhaled corticosteroids cannot modify subse-
quent development of asthma in preschool children
at high risk for asthma.57
Another observation that supports the view that
asthma can be explained by more than TH2-mediated
inflammation is found in severe asthma. Severe re-
fractory asthma is characterized by neutrophilic air-
way inflammation in the presence or absence of
eosinophils and is characterized by increased tissue
injury and remodeling. Despite the use of high doses
of inhaled corticosteroids, such patients remain
symptomatic.
From these observations Holgate et al. have intro-
duced the idea of epithelial mesenchymal trophic unit
(EMTU) (Fig. 9).58,59 They postulate that exagger-
ated inflammation and remodeling in asthmatic air-
ways are consequences of abnormal injury and repair
responses from the susceptibility of bronchial epithe-
lium to components of the inhaled environment. Air-
way inflammation and airway remodeling, in this
view, are parallel and interacting factors.
In addition, many genes and loci that are associ-
ated with increased susceptibility to asthma are ex-
pressed in the mucus and epidermis, indicating that
events at epithelial cell surfaces might also be driving
the disease process.60
THERAPEUTIC IMPLICATIONS
CORTICOSTEROIDS
Inhaled glucocorticosteroids (ICS) are currently the
most effective anti-inflammatory medications for the
treatment of persistent asthma. Most cases of asthma
are well controlled by ICS. Some studies have also
shown ICS to be effective in preventing or reducing
the decline of airway function in asthmatic patients
over time,61 with a greater benefit if therapy with ICS
is started early after asthma diagnosis.62 However,
others report no significant long term prevention in
the decline of lung function with ICS in children pre-
senting mild to moderate asthma.63 Whether or not
this decline in lung function is preventable needs to
be confirmed by further studies.
As several divergent models have been studied, the
effect of corticosteroids on epithelial cells is still con-
troversial, although they may be beneficial by stimu-
lating a decrease in mucus production. To date, the
effect of corticosteroids on fibroblasts has been
poorly studied. In one in vitro study, dexamethasone
has been shown to increase 3H-thymidine incorpora-
tion in asthmatic bronchial fibroblasts, without having
any significant effect on normal fibroblast prolifera-
tion, suggesting that the corticosteroids can influence
some aspects of the bronchial fibroblast phenotype.64
In another, the use of corticosteroids was shown to
elicit a decrease in smooth muscle cell proliferation.65
Other studies have shown that corticosteroids have
no effect on the activation of nuclear factor-B tran-
scription factor, suggesting a possible non-
immunosuppressive effect of corticosteroids on
ASM.66 Neither were they shown to be effective in re-
ducing extracellular matrix (ECM) protein produc-
tion by human ASM.67 Thus, corticosteroids may im-
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Fig. 9 The interaction between TH2 inflammation and the EMTU in 
asthma pathogenesis. A paralel model for asthma pathogenesis in which 
an inherited or acquired epithelial susceptibility to environmental agents 
leads to induction of stress-injury and repair responses is shown. Growth 
arest and prolonged repair enhances cel-cel communication within the 
EMTU, leading to myofibroblast activation and propagation of remodeling 
responses into the submucosa. At each level, TH2 cytokines are able to in-
teract with the EMTU to enhance or amplify these responses. Adapted with 
permission from Holgate and Davies D.E. Davies, J. Wicks, R.M. Powel, 
S.M. Puddicombe and S.T. Holgate, Airway remodeling in asthma: new in-
sights, J. Alergy Clin. Immunol. 2003;111:215-225.
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ICS may be effective in reducing reticular base-
ment membrane (RBM) thickness when used for a
long period of time and at high doses. Some authors
have reported that there is no change in basement
membrane thickness following either long (3,7, and
10 years68) or short (8 weeks) term use of ICS. Oth-
ers have suggested that treatments with ICS lasting 6
weeks,69 4 months, 6 months, 1 year and 2 years re-
sults in a modest decrease in basement membrane
thickness.
OTHER ASTHMA DRUGS
Cysteinyl leukotrienes (CysLT) play an important
role in the pathogenesis of airway remodeling and an-
tileukotrienes work to exert a certain degree of anti-
inflammatory effect.70 The cysteinyl leukotriene an-
tagonist Montelukast, for example, has been shown
to significantly inhibit ovalbumin induced airway
smooth muscle hyperplasia and subepithelial fibrosis
in sensitized mice. Further studies are needed, how-
ever, to fully elucidate the role of the CysLT pathway
in human asthmatic patients.
There is little evidence that β2-agonists affect air-
way structure and influence airway remodeling.
Theoretically, the synergy between β2-agonists and
glucocorticoids rests on observations that glucocorti-
coids increase expression of β2-agonist receptors,
whereas the β2-agonists facilitate nuclear transloca-
tion of the glucocorticoid receptor.
As for theophylline, there is no evidence regarding
its influence on airway remodeling.
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